UNSPSC 51172113: Ambucetamide or ambucetamide hydrochloride

This classification denotes an antispasmotic agent with the molecular formulas C17H28N2O2 and C17H28N2O2.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers 131B408RZI and 2M010V3MAJ, the base compound being chemically known as benzeneacetamide, alpha-(dibutylamino)-4-methoxy- (9ci) but generally known as ambucetamide, which bears US NIH Compound Identifier 10616. European Medicines Agency schedules Ambucetamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05400MIG and SUB00428MIG.

UNSPSC 51172113 Ambucetamide or ambucetamide hydrochloride is a Commodity code that reflects pharmaceutical manufacturing and supply arrangements for state and local health, criminal justice, and benefits administration. Recent solicitations show this code tags both direct drug-testing services — where the pharmaceutical itself is consumed as part of a screening protocol — and broader pharmacy benefit procurement where the drug may appear as one line item within multi-source generic pharmaceutical contracts serving state agencies and cooperatively purchasing jurisdictions. The work being solicited ranges from specimen collection and immunoassay screening in criminal justice settings to inclusion in statewide generic pharmaceutical frameworks serving multiple agencies and constituent jurisdictions.

Issuing bodies include Texas state agencies (Texas Health and Human Services Commission, Texas Department of Criminal Justice), county-level criminal justice departments (Collin County Community Supervision and Corrections Department), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across Oregon and Minnesota). Geographic activity centers on Texas, with cooperative purchasing extending into Minnesota and Oregon. Representative recent opportunities include Collin County's RFP for offender specimen collection and drug testing services (RFP 2026-327, due July 23, 2026, estimated contract value $600,000 for approximately 25,031 annual tests over a two-year term with optional renewal), and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products (RFP S1070000015802, due March 26, 2026), which establishes multi-award framework contracts distributed through authorized wholesalers to participating state and local facilities with contract effectiveness July 1, 2026.